<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pediatric bipolar major depression: Choosing treatment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pediatric bipolar major depression: Choosing treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pediatric bipolar major depression: Choosing treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Axelson, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Brent, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 03, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H11277123"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pediatric bipolar disorder often includes episodes of major depression. As an example, a four-year, prospective observational study of children and adolescents with bipolar disorder (n = 413) found that they were ill with major depression for 6 percent of the follow-up time and ill with subsyndromal depressive symptoms for another 12 percent of the time [<a href="#rid1">1</a>].</p><p>This topic reviews choosing treatment for pediatric bipolar major depression. Other aspects of pediatric bipolar disorder are discussed separately, including an overview of choosing treatment; general principles of using pharmacotherapy; the efficacy and core elements of adjunctive psychotherapy; assessment and diagnosis; and the epidemiology, clinical features, and course of illness:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15925.html" rel="external">"Pediatric bipolar disorder: Overview of choosing treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/98716.html" rel="external">"Pediatric bipolar disorder and pharmacotherapy: General principles"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/98754.html" rel="external">"Pediatric bipolar disorder: Efficacy and core elements of adjunctive psychotherapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/83083.html" rel="external">"Pediatric bipolar disorder: Assessment and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15924.html" rel="external">"Pediatric bipolar disorder: Clinical manifestations and course of illness"</a>.)</p><p></p><p class="headingAnchor" id="H11277255"><span class="h1">GENERAL PRINCIPLES</span><span class="headingEndMark"> — </span>A separate topic discusses the general principles for treating pediatric bipolar disorder with pharmacotherapy, including the role of the pediatrician; assessing patients prior to treatment; prescribing medications to age-appropriate patients; indications for pharmacotherapy (and electroconvulsive therapy); using monotherapy, medication combinations, and drugs that may destabilize patients; administering medications as part of comprehensive treatment; monitoring patient progress; the duration of an adequate drug trial; and information for patients and families. (See  <a class="medical medical_review" href="/d/html/98716.html" rel="external">"Pediatric bipolar disorder and pharmacotherapy: General principles"</a>.)</p><p class="headingAnchor" id="H2210983347"><span class="h1">APPROACH TO TREATMENT</span><span class="headingEndMark"> — </span>We suggest that acute treatment of pediatric bipolar major depression proceed according to the sequence described in the subsections below, which is summarized in the algorithm  (<a class="graphic graphic_algorithm graphicRef126103" href="/d/graphic/126103.html" rel="external">algorithm 1</a>). Patients receive initial pharmacotherapy and progress through each step until they respond. The duration of an adequate treatment trial is discussed separately. (See  <a class="medical medical_review" href="/d/html/98716.html" rel="external">"Pediatric bipolar disorder and pharmacotherapy: General principles", section on 'Duration of an adequate trial'</a>.)</p><p>In addition, psychotherapy is nearly always indicated as an adjuvant to pharmacotherapy for pediatric bipolar disorder. (See  <a class="medical medical_review" href="/d/html/15925.html" rel="external">"Pediatric bipolar disorder: Overview of choosing treatment", section on 'Adjunctive psychotherapy'</a>.)</p><p>Following response to acute treatment, patients receive maintenance treatment to prevent recurrences. (See <a class="local">'Using antidepressants'</a> below and  <a class="medical medical_review" href="/d/html/15925.html" rel="external">"Pediatric bipolar disorder: Overview of choosing treatment", section on 'Maintenance pharmacotherapy'</a>.)</p><p class="headingAnchor" id="H11277684"><span class="h2">Initial drugs</span><span class="headingEndMark"> — </span>Based upon randomized trials, first-line treatment for children and adolescents with bipolar major depression is either <a class="drug drug_pediatric" data-topicid="127921" href="/d/drug information/127921.html" rel="external">lurasidone</a> monotherapy or an alternative second-generation antipsychotic plus a selective serotonin reuptake inhibitor (SSRI).</p><p><a class="drug drug_pediatric" data-topicid="127921" href="/d/drug information/127921.html" rel="external">Lurasidone</a> monotherapy is started at a dose of 20 mg/day for one week; the drug is administered once daily in the evening with food [<a href="#rid2">2</a>]. Depending upon efficacy and tolerability, lurasidone is titrated up (eg, 20 mg/day each week) until the patient responds or reaches the maximum dose of 80 mg/day.</p><p>When combining a second-generation antipsychotic and an antidepressant, the two drugs are typically started simultaneously. However, for patients who are moderately ill, a reasonable alternative is to initially start only an antipsychotic; patients who respond within one to two weeks continue with antipsychotic monotherapy, whereas patients who do not respond satisfactorily receive add-on treatment with an SSRI. The second-generation antipsychotics that we use include <a class="drug drug_pediatric" data-topicid="13180" href="/d/drug information/13180.html" rel="external">aripiprazole</a>, <a class="drug drug_pediatric" data-topicid="16033" href="/d/drug information/16033.html" rel="external">olanzapine</a>, <a class="drug drug_pediatric" data-topicid="89427" href="/d/drug information/89427.html" rel="external">quetiapine</a>, and <a class="drug drug_pediatric" data-topicid="12770" href="/d/drug information/12770.html" rel="external">risperidone</a>. SSRIs typically used include <a class="drug drug_pediatric" data-topicid="13043" href="/d/drug information/13043.html" rel="external">escitalopram</a>, <a class="drug drug_pediatric" data-topicid="13315" href="/d/drug information/13315.html" rel="external">fluoxetine</a>, and <a class="drug drug_pediatric" data-topicid="12787" href="/d/drug information/12787.html" rel="external">sertraline</a>. <a class="drug drug_pediatric" data-topicid="12972" href="/d/drug information/12972.html" rel="external">Citalopram</a> is generally avoided, given the concerns about cardiac conduction problems at doses higher than 40 mg/day; <a class="drug drug_pediatric" data-topicid="12681" href="/d/drug information/12681.html" rel="external">paroxetine</a> is also not recommended given problems with withdrawal symptoms and drug interactions.</p><p>For pediatric bipolar major depression that does not respond to <a class="drug drug_pediatric" data-topicid="127921" href="/d/drug information/127921.html" rel="external">lurasidone</a> monotherapy, we suggest that clinicians continue the antipsychotic and add an SSRI.</p><p>For pediatric bipolar major depression that does not respond to a second-generation antipsychotic plus an SSRI within six to eight weeks, we suggest that clinicians continue the antipsychotic and switch to another antidepressant. We generally switch to a different SSRI by cross-tapering the two drugs over a few days to one week. If patients do not respond to the antipsychotic plus a different SSRI within six to eight weeks, we usually continue the antipsychotic and switch to another antidepressant, such as a serotonin-norepinephrine reuptake inhibitor (SNRI; eg, <a class="drug drug_pediatric" data-topicid="12878" href="/d/drug information/12878.html" rel="external">venlafaxine</a>) or <a class="drug drug_pediatric" data-topicid="12719" href="/d/drug information/12719.html" rel="external">bupropion</a>. The antidepressants are cross-tapered over one to two weeks. However, a reasonable alternative is to continue the SSRI and switch antipsychotics by cross-tapering them over one to two weeks. Additional information about switching antidepressants is discussed separately in the context of adults. (See  <a class="medical medical_review" href="/d/html/1716.html" rel="external">"Switching antidepressant medications in adults"</a>.)</p><p>A network meta-analysis and randomized trials support treatment of pediatric bipolar major depression with <a class="drug drug_pediatric" data-topicid="127921" href="/d/drug information/127921.html" rel="external">lurasidone</a> monotherapy or an alternative second-generation antipsychotic plus an SSRI:</p><p class="bulletIndent1"><span class="glyph">●</span>A network meta-analysis (four trials, 797 youths ages 10 to 18) compared second-generation antipsychotics, <a class="drug drug_pediatric" data-topicid="127921" href="/d/drug information/127921.html" rel="external">lurasidone</a>, <a class="drug drug_pediatric" data-topicid="89427" href="/d/drug information/89427.html" rel="external">quetiapine</a>, and <a class="drug drug_pediatric" data-topicid="16033" href="/d/drug information/16033.html" rel="external">olanzapine</a> plus <a class="drug drug_pediatric" data-topicid="13315" href="/d/drug information/13315.html" rel="external">fluoxetine</a> in the treatment of bipolar I major depression [<a href="#rid3">3</a>]. Treatment with either lurasidone (-5.7; 95% CI -8.66 to -2.76) or olanzapine plus fluoxetine (-5.01; 95% CI -8.63 to 1.38) resulted in improvements in the Children’s Depression Rating Scale-Revised versus placebo. Furthermore, lurasidone was associated with smaller change in weight, cholesterol, and triglycerides from baseline versus olanzapine plus fluoxetine or quetiapine.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A six-week trial compared <a class="drug drug_pediatric" data-topicid="127921" href="/d/drug information/127921.html" rel="external">lurasidone</a> (mean dose 33 mg/day) with placebo in youth with bipolar I major depression (n = 347) [<a href="#rid2">2</a>]. Adjunctive pharmacotherapy was allowed for agitation, anxiety, extrapyramidal symptoms, and insomnia; stimulants were permitted for comorbid attention deficit hyperactivity disorder. Response (reduction of baseline depressive symptoms ≥50 percent) occurred in more patients treated with lurasidone than placebo (60 versus 37 percent). Improvement of anxiety and functioning was also greater with lurasidone. Discontinuation of treatment due to adverse effects was identical with lurasidone and placebo (2 percent). The most frequent adverse events with lurasidone were nausea (16 percent of patients) and somnolence (11 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An eight-week trial compared placebo with <a class="drug drug_pediatric" data-topicid="16033" href="/d/drug information/16033.html" rel="external">olanzapine</a> plus <a class="drug drug_pediatric" data-topicid="13315" href="/d/drug information/13315.html" rel="external">fluoxetine</a> in children and adolescents with bipolar major depression (n = 255) [<a href="#rid4">4</a>]. Olanzapine was initiated at 3 mg/day and the final mean dose was 8 mg/day; fluoxetine was started at 25 mg/day and the final mean dose was 38 mg/day. Remission occurred in more patients treated with olanzapine/fluoxetine than placebo (59 versus 43 percent), and the median time to remission with active drug was approximately seven weeks. In addition, switching to mania was comparable for active drug and placebo (1 and 0 percent). However, discontinuation of treatment due to adverse effects was more than twice as high in patients receiving olanzapine/fluoxetine than placebo (14 and 6 percent). Mean weight gain was greater with olanzapine/fluoxetine than placebo (4.4 versus 0.5 kg), and the incidence of sedation, tremor, hyperlipidemia, or hyperprolactinemia was greater with olanzapine/fluoxetine. Increases in heart rate and corrected QT interval were also greater with olanzapine/fluoxetine.</p><p></p><p>The efficacy of <a class="drug drug_pediatric" data-topicid="127921" href="/d/drug information/127921.html" rel="external">lurasidone</a> monotherapy and of <a class="drug drug_pediatric" data-topicid="16033" href="/d/drug information/16033.html" rel="external">olanzapine</a> plus <a class="drug drug_pediatric" data-topicid="13315" href="/d/drug information/13315.html" rel="external">fluoxetine</a> for short-term treatment of bipolar major depression in youth is consistent with results from randomized trials in adults with bipolar major depression. (See  <a class="medical medical_review" href="/d/html/16693.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of second-generation antipsychotics", section on 'Lurasidone'</a> and  <a class="medical medical_review" href="/d/html/14655.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of antidepressants", section on 'Olanzapine plus fluoxetine'</a>.)</p><p>Indirect evidence supporting the use of <a class="drug drug_pediatric" data-topicid="89427" href="/d/drug information/89427.html" rel="external">quetiapine</a> and <a class="drug drug_pediatric" data-topicid="12770" href="/d/drug information/12770.html" rel="external">risperidone</a> for bipolar major depression includes randomized trials in adults. (See  <a class="medical medical_review" href="/d/html/16693.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of second-generation antipsychotics", section on 'Efficacy'</a>.)</p><p>Multiple randomized trials that compared <a class="drug drug_pediatric" data-topicid="89427" href="/d/drug information/89427.html" rel="external">quetiapine</a> monotherapy with placebo for eight weeks in youth with bipolar major depression have found that quetiapine was not superior; however, placebo response rates were high in these trials, calling into question the apparent lack of benefit [<a href="#rid5">5</a>]. One trial found that response (reduction of baseline symptoms ≥50 percent) to placebo (n = 100 patients) occurred in 55 percent [<a href="#rid6">6</a>], and a second trial found that response to placebo (n = 15) occurred in 10 patients (67 percent) [<a href="#rid7">7</a>].</p><p><a class="drug drug_pediatric" data-topicid="13180" href="/d/drug information/13180.html" rel="external">Aripiprazole</a> has been studied in prospective observational studies of pediatric bipolar major depression [<a href="#rid8">8</a>], and the drug is generally not sedating and has a favorable metabolic profile relative to some other antipsychotics used for pediatric bipolar disorder. (See  <a class="medical medical_review" href="/d/html/98719.html" rel="external">"Pediatric mania and second-generation antipsychotics: Efficacy, administration, and side effects", section on 'Weight gain'</a>.)</p><p>In patients with pediatric bipolar major depression who do not respond to initial treatment with a second-generation antipsychotic plus an SSRI, indirect evidence that supports switching the SSRI to a second SSRI or to <a class="drug drug_pediatric" data-topicid="12878" href="/d/drug information/12878.html" rel="external">venlafaxine</a> includes randomized trials in youth and in adults with unipolar major depression. (See  <a class="medical medical_review" href="/d/html/1227.html" rel="external">"Pediatric unipolar depression and pharmacotherapy: Choosing a medication", section on 'Second-line'</a> and  <a class="medical medical_review" href="/d/html/14685.html" rel="external">"Unipolar depression in adults: Choosing treatment for resistant depression", section on 'Antidepressants'</a>.)</p><p class="headingAnchor" id="H4102417861"><span class="h3">Using antidepressants</span><span class="headingEndMark"> — </span>It is reasonable to prescribe antidepressants for pediatric bipolar major depression, provided that antimanic drugs such as a second-generation antipsychotics or <a class="drug drug_pediatric" data-topicid="12559" href="/d/drug information/12559.html" rel="external">lithium</a> are also used [<a href="#rid9">9</a>]. However, antidepressants should not be used in bipolar major depression with mixed features (symptoms of mania/hypomania).</p><p>Patients treated with antidepressants are monitored for symptoms of mania (eg, irritability, mood lability, agitation, or other mood symptoms). Although a randomized trial [<a href="#rid4">4</a>] and a prospective observational study [<a href="#rid10">10</a>] both indicate that antidepressants do not increase the risk of treatment emergent mania, other observational studies have raised persistent concerns that antidepressants may destabilize children and adolescents with bipolar disorder [<a href="#rid11">11-15</a>].</p><p>For patients with bipolar depression who are successfully treated with adjunctive antidepressants and remain stable for several (eg, three to six) months, we suggest slowly tapering the antidepressant (eg, over two to four months) and discontinuing the antidepressant, unless this has precipitated relapse in the past.</p><p>Additional information about the use of adjunctive antidepressants in bipolar major depression, including the role and efficacy of antidepressants and the risk of switching to mania, is discussed separately in the context of adults. (See  <a class="medical medical_review" href="/d/html/14655.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of antidepressants"</a>.)</p><p class="headingAnchor" id="H11277784"><span class="h2">Treatment-resistant patients</span><span class="headingEndMark"> — </span>Pediatric bipolar major depression often does not respond sufficiently to multiple (eg, two to three) trials of a second-generation antipsychotic plus an antidepressant. For these treatment-resistant patients, we suggest <a class="drug drug_pediatric" data-topicid="12542" href="/d/drug information/12542.html" rel="external">lamotrigine</a>, <a class="drug drug_pediatric" data-topicid="12559" href="/d/drug information/12559.html" rel="external">lithium</a>, or omega-3 fatty acids (n-3 polyunsaturated fatty acids). If patients partially responded to a second-generation antipsychotic plus an antidepressant, we add lamotrigine, lithium, or omega-3 fatty acids to the existing regimen. If there was little to no response to the antipsychotic plus antidepressant, we discontinue the antidepressant and add lamotrigine, lithium, or omega-3 fatty acids to the antipsychotic; however, a reasonable alternative is to discontinue both the antipsychotic and antidepressant, and to start lamotrigine or lithium monotherapy. Omega-3 fatty acids are rarely used as monotherapy.</p><p>Patients unresponsive to either <a class="drug drug_pediatric" data-topicid="12542" href="/d/drug information/12542.html" rel="external">lamotrigine</a> or <a class="drug drug_pediatric" data-topicid="12559" href="/d/drug information/12559.html" rel="external">lithium</a> (as add-on treatment or monotherapy) are switched to the other drug by cross-tapering them over one to two weeks. Omega-3 fatty acids can be added at any point during treatment because they are well tolerated.</p><p>Administration of <a class="drug drug_pediatric" data-topicid="12542" href="/d/drug information/12542.html" rel="external">lamotrigine</a> and <a class="drug drug_pediatric" data-topicid="12559" href="/d/drug information/12559.html" rel="external">lithium</a> are discussed separately. (See  <a class="medical medical_review" href="/d/html/15925.html" rel="external">"Pediatric bipolar disorder: Overview of choosing treatment", section on 'Treatment-refractory patients'</a> and  <a class="medical medical_review" href="/d/html/15925.html" rel="external">"Pediatric bipolar disorder: Overview of choosing treatment", section on 'Treatment-resistant patients'</a>.)</p><p>In using omega-3 fatty acids, we prefer formulations with a ratio of eicosapentaenoic acid to docosahexaenoic acid of approximately two to one. The dose is typically 500 to 1000 mg twice per day.</p><p>Antidepressants should generally be tapered before discontinuation. A taper of approximately 25 to 50 percent per week provides a gradual decrease that allows the body time to adjust to the lower dose. As an example, <a class="drug drug_pediatric" data-topicid="12787" href="/d/drug information/12787.html" rel="external">sertraline</a> 200 mg per day can be decreased to 150 mg per day for week 1, 100 mg per day for week 2, 50 mg per day for week 3, and 25 mg per day for week 4, after which the medication is stopped. However, the half-life of <a class="drug drug_pediatric" data-topicid="13315" href="/d/drug information/13315.html" rel="external">fluoxetine</a> is long enough such that abrupt discontinuation generally does not cause problems. Additional information about discontinuing antidepressants is discussed separately. (See  <a class="medical medical_review" href="/d/html/105323.html" rel="external">"Discontinuing antidepressant medications in adults"</a>.)</p><p>Second-generation antipsychotics that are discontinued are generally tapered over one to two weeks before the drug is stopped.</p><p>Using <a class="drug drug_pediatric" data-topicid="12542" href="/d/drug information/12542.html" rel="external">lamotrigine</a> to treat pediatric bipolar major depression is supported by small observational studies [<a href="#rid16">16-18</a>]. As an example, an eight-week prospective study included 19 adolescents who were treated with lamotrigine (typically as monotherapy), which was started at 10 to 25 mg/day and slowly increased over several weeks to a mean final dose of 132 mg/day [<a href="#rid8">8</a>]. Remission occurred in 11 patients (58 percent). The most frequent side effects were headache, fatigue, nausea, and diaphoresis.</p><p>Small observational studies also suggest that <a class="drug drug_pediatric" data-topicid="12559" href="/d/drug information/12559.html" rel="external">lithium</a> may help pediatric bipolar major depression. A six-week prospective study included 27 hospitalized adolescents with bipolar major depression (including patients with psychotic features), who were treated with lithium monotherapy that was prescribed to achieve a target serum concentration of 1 to 1.2 mEq/L (1 to 1.2 mmol/L) [<a href="#rid19">19</a>]. Remission occurred in eight patients (30 percent). Mean weight gain was 1.7 kg; other adverse effects included headache, gastrointestinal distress, polyuria, and polydipsia.</p><p>Indirect evidence supporting the use of omega-3 fatty acids includes two small randomized trials:</p><p class="bulletIndent1"><span class="glyph">●</span>A 12-week trial enrolled children 5 to 12 years of age with manic, hypomanic, or mixed (mood elevated plus depressive) symptoms; the study included a treatment arm (n = 7 patients) with omega-3 fatty acid monotherapy (3000 mg/day) [<a href="#rid20">20</a>]. Improvement of baseline depressive symptoms ≥50 percent occurred in three patients (43 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another 12-week trial randomly assigned youth 7 to 14 years of age with subsyndromal bipolar disorder to one of four treatments: omega-3 fatty acids (2000 mg/day) plus individual family psychoeducational psychotherapy (n = 5), omega-3 plus active monitoring (n = 5), placebo plus individual family psychoeducational psychotherapy (n = 7), or placebo plus active monitoring (n = 6) [<a href="#rid21">21</a>]. Improvement on one of the depression rating scales was superior with omega-3 plus individual family psychoeducational psychotherapy, compared with placebo plus active monitoring. However, omega-3 plus active monitoring provided no advantage over placebo plus active monitoring.</p><p></p><p>In addition, randomized trials in adults with bipolar major depression suggest omega-3 fatty acids may be beneficial. (See  <a class="medical medical_review" href="/d/html/15267.html" rel="external">"Bipolar major depression in adults: Choosing treatment"</a>.)</p><p class="headingAnchor" id="H11277934"><span class="h2">Treatment-refractory patients</span><span class="headingEndMark"> — </span>For children and adolescents with bipolar major depression who do not respond to initial and subsequent treatment, we suggest other medication combinations, such as <a class="drug drug_pediatric" data-topicid="12542" href="/d/drug information/12542.html" rel="external">lamotrigine</a> plus <a class="drug drug_pediatric" data-topicid="12559" href="/d/drug information/12559.html" rel="external">lithium</a>. However, a reasonable alternative is to add an antidepressant (eg, SSRI, SNRI, or <a class="drug drug_pediatric" data-topicid="12719" href="/d/drug information/12719.html" rel="external">bupropion</a>) to lithium, based upon observational studies [<a href="#rid22">22,23</a>]. As an example, a retrospective study of youth with bipolar disorder (n = 42) found that improvement of depressive symptoms was seven times more likely to occur in patients who received an SSRI as part of treatment than patients who did not [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H1261485131"><span class="h2">Other options</span><span class="headingEndMark"> — </span>Other treatment options for pediatric bipolar major depression that does not respond to pharmacotherapy include adjunctive bright light therapy and electroconvulsive therapy (ECT).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive bright light therapy</strong> – Adjunctive bright light therapy is an option for patients who respond insufficiently to their treatment regimen but do not want to add a medication or switch medications. Light therapy is added to treatment regimens that include medications that can prevent episodes of mania and hypomania, such as second-generation antipsychotics, <a class="drug drug_pediatric" data-topicid="12542" href="/d/drug information/12542.html" rel="external">lamotrigine</a>, or <a class="drug drug_pediatric" data-topicid="12559" href="/d/drug information/12559.html" rel="external">lithium</a>. However, many children and adolescents decline light therapy because it necessitates sitting in front of a light box for a minimum of 30 minutes every day. The administration, safety, and side effects of bright light therapy are discussed in the context of seasonal affective disorder. (See  <a class="medical medical_review" href="/d/html/101250.html" rel="external">"Seasonal affective disorder: Treatment", section on 'Bright light therapy'</a>.)</p><p></p><p class="bulletIndent1">Indirect evidence supports the use of add-on bright light therapy for nonseasonal pediatric bipolar major depression. As an example, randomized trials in adults with nonseasonal, unipolar depression suggest that adjunctive light therapy may be efficacious. (See  <a class="medical medical_review" href="/d/html/90155.html" rel="external">"Unipolar depression in adults: Investigational and nonstandard treatment", section on 'Bright light therapy'</a>.)</p><p></p><p class="bulletIndent1">In addition, an observational study in adults with nonseasonal bipolar depression (n = 9) [<a href="#rid24">24</a>] and a randomized trial in youth with seasonal affective disorder (n = 28) [<a href="#rid25">25</a>] suggest that bright light therapy may be helpful. However, an eight-week randomized trial that compared adjunctive light therapy with a placebo condition in adults with bipolar depression (n = 44) found that active treatment was not beneficial [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electroconvulsive therapy</strong> – For children and adolescents with severe, persistent, and disabling bipolar major depression that is unresponsive to multiple (eg, four or five) pharmacotherapy trials, we suggest ECT. This approach is consistent with treatment guidelines [<a href="#rid9">9,27</a>]. In particular, indications for ECT include suicidal plans plus intent, suicidal behavior, catatonia, or psychotic features. ECT is used infrequently for adolescents and rarely for younger children [<a href="#rid28">28</a>]. Evidence supporting the use of ECT includes retrospective studies in youth [<a href="#rid27">27,29-31</a>], as well as randomized trials in adult bipolar major depression. (See  <a class="medical medical_review" href="/d/html/14659.html" rel="external">"Bipolar disorder in adults: Indications for and efficacy of electroconvulsive therapy", section on 'Bipolar major depression'</a>.)</p><p></p><p class="headingAnchor" id="H1490585"><span class="h1">COMORBID DISORDERS</span><span class="headingEndMark"> — </span>Treatment of pediatric bipolar disorder that is comorbid with attention deficit hyperactivity disorder or anxiety disorders is discussed separately. (See  <a class="medical medical_review" href="/d/html/15925.html" rel="external">"Pediatric bipolar disorder: Overview of choosing treatment", section on 'Comorbid disorders'</a>.)</p><p class="headingAnchor" id="H11278374"><span class="h1">MAINTENANCE TREATMENT</span><span class="headingEndMark"> — </span>Children and adolescents with an acute bipolar major depressive episode who respond to acute pharmacotherapy usually receive the same regimen as maintenance treatment unless the regimen is poorly tolerated. Maintenance treatment for pediatric bipolar disorder is discussed separately. (See  <a class="medical medical_review" href="/d/html/15925.html" rel="external">"Pediatric bipolar disorder: Overview of choosing treatment", section on 'Maintenance pharmacotherapy'</a>.)</p><p>Pediatric bipolar major depression may respond to an acute regimen that includes an antidepressant. The use of antidepressants in maintenance treatment is discussed elsewhere in this topic. (See <a class="local">'Using antidepressants'</a> above.)</p><p class="headingAnchor" id="H11278352"><span class="h1">ADJUNCTIVE PSYCHOTHERAPY</span><span class="headingEndMark"> — </span>Psychotherapy is nearly always indicated as an adjuvant to pharmacotherapy for pediatric bipolar disorder. If symptoms are not responding adequately to psychotherapy, the frequency and/or intensity is increased (through multiple visits per week, intensive outpatient program, or partial hospitalization program). The use of psychotherapy for bipolar depression in youth is consistent with practice guidelines [<a href="#rid32">32</a>].</p><p>Choosing adjunctive psychotherapy for patients with bipolar major depression is discussed separately. (See  <a class="medical medical_review" href="/d/html/15925.html" rel="external">"Pediatric bipolar disorder: Overview of choosing treatment", section on 'Adjunctive psychotherapy'</a>.)</p><p class="headingAnchor" id="H393080728"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115361.html" rel="external">"Society guideline links: Bipolar disorder"</a>.)</p><p class="headingAnchor" id="H3914175121"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/140703.html" rel="external">"Patient education: Depression in children and teens (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/15342.html" rel="external">"Patient education: Depression in adults (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/16163.html" rel="external">"Patient education: Medicines for depression (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/15348.html" rel="external">"Patient education: Bipolar disorder (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/83813.html" rel="external">"Patient education: When you have depression and another health problem (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/4867.html" rel="external">"Patient education: Depression in children and adolescents (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/4870.html" rel="external">"Patient education: Depression treatment options for children and adolescents (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/4869.html" rel="external">"Patient education: Bipolar disorder (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/4868.html" rel="external">"Patient education: Depression in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H11278230"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>For initial treatment of pediatric bipolar major depression, we suggest either <a class="drug drug_pediatric" data-topicid="127921" href="/d/drug information/127921.html" rel="external">lurasidone</a> monotherapy or a different second-generation antipsychotic plus a selective serotonin reuptake inhibitor (SSRI), rather than other medication regimens  (<a class="graphic graphic_algorithm graphicRef126103" href="/d/graphic/126103.html" rel="external">algorithm 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). If patients do not respond to lurasidone monotherapy, we typically continue the drug and add an SSRI. If patients do not respond to an antipsychotic and SSRI combination, we typically continue the antipsychotic and switch antidepressants. However, a reasonable alternative is to continue the initial antidepressant and switch to a different second-generation antipsychotic. (See <a class="local">'Initial drugs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pediatric bipolar major depression that does not respond to a second-generation antipsychotic plus an antidepressant can be treated with <a class="drug drug_pediatric" data-topicid="12542" href="/d/drug information/12542.html" rel="external">lamotrigine</a>, <a class="drug drug_pediatric" data-topicid="12559" href="/d/drug information/12559.html" rel="external">lithium</a>, or omega-3 fatty acids:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If patients partially responded to a second-generation antipsychotic plus an antidepressant, we add <a class="drug drug_pediatric" data-topicid="12542" href="/d/drug information/12542.html" rel="external">lamotrigine</a>, <a class="drug drug_pediatric" data-topicid="12559" href="/d/drug information/12559.html" rel="external">lithium</a>, or omega-3 fatty acids to the existing regimen.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If there was little to no response to the antipsychotic plus antidepressant, we discontinue the antidepressant and add <a class="drug drug_pediatric" data-topicid="12542" href="/d/drug information/12542.html" rel="external">lamotrigine</a>, <a class="drug drug_pediatric" data-topicid="12559" href="/d/drug information/12559.html" rel="external">lithium</a>, or omega-3 fatty acids to the antipsychotic; however, a reasonable alternative is to discontinue both the antipsychotic and antidepressant, and to start lamotrigine or lithium monotherapy. Omega-3 fatty acids are rarely used as monotherapy. (See <a class="local">'Treatment-resistant patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other treatment options for bipolar major depression include medication combinations such as <a class="drug drug_pediatric" data-topicid="12542" href="/d/drug information/12542.html" rel="external">lamotrigine</a> plus <a class="drug drug_pediatric" data-topicid="12559" href="/d/drug information/12559.html" rel="external">lithium</a> or lithium plus an antidepressant, as well as adjunctive bright light therapy. We use electroconvulsive therapy (ECT) for severe, persistent, and disabling bipolar major depression that is unresponsive to several (eg, four to five) pharmacotherapy trials. (See <a class="local">'Treatment-refractory patients'</a> above and <a class="local">'Other options'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For severe bipolar depression with catatonia, we suggest ECT rather than other treatment regimens (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Other options'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children and adolescents with an acute bipolar major depressive episode who respond to acute pharmacotherapy usually receive maintenance treatment unless the regimen is poorly tolerated. (See <a class="local">'Maintenance treatment'</a> above and  <a class="medical medical_review" href="/d/html/15925.html" rel="external">"Pediatric bipolar disorder: Overview of choosing treatment", section on 'Maintenance pharmacotherapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Psychotherapy is nearly always indicated as an adjuvant to pharmacotherapy for pediatric bipolar disorder. (See  <a class="medical medical_review" href="/d/html/15925.html" rel="external">"Pediatric bipolar disorder: Overview of choosing treatment", section on 'Adjunctive psychotherapy'</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Birmaher B, Axelson D, Goldstein B, et al. Four-year longitudinal course of children and adolescents with bipolar spectrum disorders: the Course and Outcome of Bipolar Youth (COBY) study. Am J Psychiatry 2009; 166:795.</a></li><li><a class="nounderline abstract_t">DelBello MP, Goldman R, Phillips D, et al. Efficacy and Safety of Lurasidone in Children and Adolescents With Bipolar I Depression: A Double-Blind, Placebo-Controlled Study. J Am Acad Child Adolesc Psychiatry 2017; 56:1015.</a></li><li><a class="nounderline abstract_t">DelBello MP, Kadakia A, Heller V, et al. Systematic Review and Network Meta-analysis: Efficacy and Safety of Second-Generation Antipsychotics in Youths With Bipolar Depression. J Am Acad Child Adolesc Psychiatry 2022; 61:243.</a></li><li><a class="nounderline abstract_t">Detke HC, DelBello MP, Landry J, Usher RW. Olanzapine/Fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2015; 54:217.</a></li><li class="breakAll">Thomas-Lakia T, Levy J, Findling RL. Bipolar disorders. In: Clinical Manual of Child and Adolescent Psychopharmacology, Third Edition, McVoy M, Findling RL (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.264.</li><li><a class="nounderline abstract_t">Findling RL, Pathak S, Earley WR, et al. Efficacy and safety of extended-release quetiapine fumarate in youth with bipolar depression: an 8 week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol 2014; 24:325.</a></li><li><a class="nounderline abstract_t">DelBello MP, Chang K, Welge JA, et al. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord 2009; 11:483.</a></li><li><a class="nounderline abstract_t">Chang K, Saxena K, Howe M. An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry 2006; 45:298.</a></li><li><a class="nounderline abstract_t">McClellan J, Kowatch R, Findling RL, Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:107.</a></li><li><a class="nounderline abstract_t">Geller B, Craney JL, Bolhofner K, et al. Two-year prospective follow-up of children with a prepubertal and early adolescent bipolar disorder phenotype. Am J Psychiatry 2002; 159:927.</a></li><li><a class="nounderline abstract_t">Biederman J, Mick E, Spencer TJ, et al. Therapeutic dilemmas in the pharmacotherapy of bipolar depression in the young. J Child Adolesc Psychopharmacol 2000; 10:185.</a></li><li><a class="nounderline abstract_t">Scheffer RE, Tripathi A, Kirkpatrick FG, Schultz T. Guidelines for treatment-resistant mania in children with bipolar disorder. J Psychiatr Pract 2011; 17:186.</a></li><li><a class="nounderline abstract_t">Faedda GL, Baldessarini RJ, Glovinsky IP, Austin NB. Treatment-emergent mania in pediatric bipolar disorder: a retrospective case review. J Affect Disord 2004; 82:149.</a></li><li><a class="nounderline abstract_t">Baumer FM, Howe M, Gallelli K, et al. A pilot study of antidepressant-induced mania in pediatric bipolar disorder: Characteristics, risk factors, and the serotonin transporter gene. Biol Psychiatry 2006; 60:1005.</a></li><li><a class="nounderline abstract_t">Goldstein BI, Birmaher B, Carlson GA, et al. The International Society for Bipolar Disorders Task Force report on pediatric bipolar disorder: Knowledge to date and directions for future research. Bipolar Disord 2017; 19:524.</a></li><li><a class="nounderline abstract_t">Carandang CG, Maxwell DJ, Robbins DR, Oesterheld JR. Lamotrigine in adolescent mood disorders. J Am Acad Child Adolesc Psychiatry 2003; 42:750.</a></li><li><a class="nounderline abstract_t">Soutullo CA, Díez-Suárez A, Figueroa-Quintana A. Adjunctive lamotrigine treatment for adolescents with bipolar disorder: retrospective report of five cases. J Child Adolesc Psychopharmacol 2006; 16:357.</a></li><li><a class="nounderline abstract_t">Shon SH, Joo Y, Lee JS, Kim HW. Lamotrigine treatment of adolescents with unipolar and bipolar depression: a retrospective chart review. J Child Adolesc Psychopharmacol 2014; 24:285.</a></li><li><a class="nounderline abstract_t">Patel NC, DelBello MP, Bryan HS, et al. Open-label lithium for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry 2006; 45:289.</a></li><li><a class="nounderline abstract_t">Wozniak J, Faraone SV, Chan J, et al. A randomized clinical trial of high eicosapentaenoic acid omega-3 fatty acids and inositol as monotherapy and in combination in the treatment of pediatric bipolar spectrum disorders: a pilot study. J Clin Psychiatry 2015; 76:1548.</a></li><li><a class="nounderline abstract_t">Fristad MA, Young AS, Vesco AT, et al. A Randomized Controlled Trial of Individual Family Psychoeducational Psychotherapy and Omega-3 Fatty Acids in Youth with Subsyndromal Bipolar Disorder. J Child Adolesc Psychopharmacol 2015; 25:764.</a></li><li><a class="nounderline abstract_t">Findling RL, McNamara NK, Gracious BL, et al. Combination lithium and divalproex sodium in pediatric bipolarity. J Am Acad Child Adolesc Psychiatry 2003; 42:895.</a></li><li><a class="nounderline abstract_t">Kowatch RA, Sethuraman G, Hume JH, et al. Combination pharmacotherapy in children and adolescents with bipolar disorder. Biol Psychiatry 2003; 53:978.</a></li><li><a class="nounderline abstract_t">Sit D, Wisner KL, Hanusa BH, et al. Light therapy for bipolar disorder: a case series in women. Bipolar Disord 2007; 9:918.</a></li><li><a class="nounderline abstract_t">Swedo SE, Allen AJ, Glod CA, et al. A controlled trial of light therapy for the treatment of pediatric seasonal affective disorder. J Am Acad Child Adolesc Psychiatry 1997; 36:816.</a></li><li><a class="nounderline abstract_t">Dauphinais DR, Rosenthal JZ, Terman M, et al. Controlled trial of safety and efficacy of bright light therapy vs. negative air ions in patients with bipolar depression. Psychiatry Res 2012; 196:57.</a></li><li><a class="nounderline abstract_t">Ghaziuddin N, Kutcher SP, Knapp P, et al. Practice parameter for use of electroconvulsive therapy with adolescents. J Am Acad Child Adolesc Psychiatry 2004; 43:1521.</a></li><li class="breakAll">Connor DF. Electroconvulsive therapy, transcranial magnetic stimulation, and deep brain stimulation. In: Dulcan's Textbook of Child and Adolescent Psychiatry, Dulcan MK (Ed), American Psychiatric Publishing, Inc, Washington, DC 2010. p.795.</li><li><a class="nounderline abstract_t">Walter G, Rey JM. Has the practice and outcome of ECT in adolescents changed? findings from a whole-population study. J ECT 2003; 19:84.</a></li><li><a class="nounderline abstract_t">Rey JM, Walter G. Half a century of ECT use in young people. Am J Psychiatry 1997; 154:595.</a></li><li><a class="nounderline abstract_t">Stein D, Weizman A, Bloch Y. Electroconvulsive therapy and transcranial magnetic stimulation: can they be considered valid modalities in the treatment of pediatric mood disorders? Child Adolesc Psychiatr Clin N Am 2006; 15:1035.</a></li><li><a class="nounderline abstract_t">Kendall T, Morriss R, Mayo-Wilson E, et al. Assessment and management of bipolar disorder: summary of updated NICE guidance. BMJ 2014; 349:g5673.</a></li></ol></div><div id="topicVersionRevision">Topic 99164 Version 9.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19448190" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Four-year longitudinal course of children and adolescents with bipolar spectrum disorders: the Course and Outcome of Bipolar Youth (COBY) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29173735" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Efficacy and Safety of Lurasidone in Children and Adolescents With Bipolar I Depression: A Double-Blind, Placebo-Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34420839" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Systematic Review and Network Meta-analysis: Efficacy and Safety of Second-Generation Antipsychotics in Youths With Bipolar Depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25721187" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Olanzapine/Fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25721187" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Olanzapine/Fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24956042" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Efficacy and safety of extended-release quetiapine fumarate in youth with bipolar depression: an 8 week, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19624387" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16540814" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17195735" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12042179" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Two-year prospective follow-up of children with a prepubertal and early adolescent bipolar disorder phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11052408" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Therapeutic dilemmas in the pharmacotherapy of bipolar depression in the young.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21586996" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Guidelines for treatment-resistant mania in children with bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15465590" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Treatment-emergent mania in pediatric bipolar disorder: a retrospective case review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16945343" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A pilot study of antidepressant-induced mania in pediatric bipolar disorder: Characteristics, risk factors, and the serotonin transporter gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28944987" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The International Society for Bipolar Disorders Task Force report on pediatric bipolar disorder: Knowledge to date and directions for future research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12819432" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Lamotrigine in adolescent mood disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16768643" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Adjunctive lamotrigine treatment for adolescents with bipolar disorder: retrospective report of five cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24813210" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Lamotrigine treatment of adolescents with unipolar and bipolar depression: a retrospective chart review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16540813" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Open-label lithium for the treatment of adolescents with bipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26646031" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A randomized clinical trial of high eicosapentaenoic acid omega-3 fatty acids and inositol as monotherapy and in combination in the treatment of pediatric bipolar spectrum disorders: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26682997" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A Randomized Controlled Trial of Individual Family Psychoeducational Psychotherapy and Omega-3 Fatty Acids in Youth with Subsyndromal Bipolar Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12874490" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Combination lithium and divalproex sodium in pediatric bipolarity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12788243" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Combination pharmacotherapy in children and adolescents with bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18076544" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Light therapy for bipolar disorder: a case series in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9183137" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A controlled trial of light therapy for the treatment of pediatric seasonal affective disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22424890" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Controlled trial of safety and efficacy of bright light therapy vs. negative air ions in patients with bipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15564821" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Practice parameter for use of electroconvulsive therapy with adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15564821" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Practice parameter for use of electroconvulsive therapy with adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12792456" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Has the practice and outcome of ECT in adolescents changed? findings from a whole-population study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9137112" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Half a century of ECT use in young people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16952774" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Electroconvulsive therapy and transcranial magnetic stimulation: can they be considered valid modalities in the treatment of pediatric mood disorders?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25258392" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Assessment and management of bipolar disorder: summary of updated NICE guidance.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
